Testing an inhaled drug for the treatment of pancreatic cancer

According to RCO News Agency, Pancreatic or pancreatic cancer is known as its offensive nature and receives nearly 6,000 victims in the United States annually.

Now a pioneering approach led by a team of scientists at the University of Rice, including James Tour, chemist James Tour, has the potential to create a revolution in pancreatic cancer treatment, one of the most deadly types of cancer with scarce medical options.

Researchers have created a targeted drug delivery through the nose that uses a drug called WR-1 or Amifostine, which is traditionally prescribed intravenously to eliminate the challenges of pancreatic cancer treatment. .

The proximity of the pancreas to vital organs such as the small intestine complicates the treatment strategies of pancreatic cancer, as high -dose radiation therapy often results in severe digestive complications.

Smell cancer

For patients with non -harvesting tumors, the options are extremely limited. This new study, which has been upgraded to Phases 1 and 2 of the clinical trial, seeks to protect healthy tissues from radiation damage, thereby improving the results of patients in a field that requires innovation.

James Tor, a professor of chemistry at the University of Rice, said: “We are moving the boundaries of radiation therapy while protecting healthy texture.” We hope this progress will soon help patients who had limited treatment options.

The basis of this innovative work can be tracked up to two decades ago, which is rooted in James Tour research with the IAEA Budget of Advanced Defense Research Projects (DARPA), which examined solutions to nanoparticles for radiation -related radiation scenarios.

As the project evolved, it paved the way for the reuse of amyfustine, an drug initially developed in the Walter Reed Medical Center in the 1980s.

The amyphustine, approved by the US Food and Drug Administration (FDA) for intravenous use, protects the healthy tissues around the radiation of tumors.

Although intravenous intravenous administration is effective, its associated side effects, such as nausea and hypertension, have prevented it from being widely accepted among physicians and patients.

On the other hand, the researchers found that oral amyphostine can be selectively protect the digestive tract from radiation while minimizing adverse effects.

However, the challenge was that gastric acids often break down the drug before reaching the intestine.

Nose

After facing the financial challenges that stopped the study, the project has accelerated by joint efforts at the Anderson Cancer Center.

Prefabricated studies on rat models promised significant promises. The mice that received oral amyphostine along with simulated radiation treatment showed a 5 % survival rate after 5 days, while their untreated counterparts did not survive.

In addition, the combination of amophyteine ​​with stereotactic body radiotherapy in the pancreatic tumor model almost tripled the time of survival, indicating that similar human results can significantly improve the patient’s condition.

The initiative of the inhalation of amophobostin is using a special tube or an edible tablet with a special coating designed to bypass gastric acids and effectively directs amyphostin directly to the upper part of the gastrointestinal tract.

Targeting this vital area without systemic side effects protects healthy cells from radiation damage.

Guy Yachin, one of the founders and CEOs of the Zerinth Biotechnology Startup (Xerient), who collaborates with the University of Rice and Anderson Lab, said: “Double is especially vulnerable to pancreatic cancer during radiation therapy, and our approach protects and protects this organs. At the same time, more aggressive treatment allows pancreatic tumors.

Historically, high -dose beams have been used to improve survival in patients with pancreatic cancer. However, its application is often limited due to concerns about being toxic to the digestive tract at high doses.

This new study shows that higher doses may be essential for effective eradication of the tumor, thereby removing the long -term gap in therapeutic options.

“High -dose radiation has always been theoretical, but we have not had the tools to protect the healthy tissues around,” Yachin added. This innovation can ultimately turn that theory into action.

The team is thrilled to start its clinical experiments with the imminent confirmation of the FDA.

These trials accurately evaluate the safety and effectiveness of the inhaled delivery method from the precise delivery of the drug to the duodenal and accelerate the transfer to the clinical use.

This new approach, by examining the complex challenges of pancreatic cancer treatment, promises significant improvement for patients who face one of the toughest battles against cancer.

The end of the message